Aggravation of symptomatic occipital epilepsy of childhood by carbamazepine

Pogoršanje simptomatske okcipitalne dečje epilepsije izazvano karbamazepinom

Fadil E. Škrijelj, Mersudin Mulić
State University of Novi Pazar, Novi Pazar, Serbia

Abstract

Introduction. Carbamazepine can lead to aggravation of epileptic seizures in generalized epilepsies (primary or secondary) with clinical manifestations of absence (typical or atypical) and/or myoclonic seizures. However, some focal epilepsies can be also aggravated by the introduction of carbamazepine. Case report. We presented a 10-year-old boy born after a complicated and prolonged delivery completed by vacuum extraction, of early psychomotor development within normal limits. At the age of 8 years he had the first epileptic seizure of simple occipital type with generalization and urination. Brain magnetic resonance imaging (MRI) showed focal cortical reductions in the left parietal and occipital regions. Interictal EEG recorded slowed basic activities above the posterior regions of the left hemisphere, with intermittent occurrence of occipital sharp waves and bicorotical sharp and slow-wave complexes. Initially, treatment with valproate was administered; however, the addition of carbamazepine into therapy induced aggravation of seizures and EEG findings, changed behavior and poor performance at school. By withdrawal of carbamazepine the condition improved both clinically and in EEG findings.

Conclusion. Childhood occipital epilepsy lesions show deterioration due to carbamazepine, which if administered induces aggravation of seizures, behavior changes, cognition with occurrence of long-term bilateral discharges, and posterior sharp and slow-wave high amplitude complexes recorded by EEG.

Key words: epilepsies, partial; seizures; valproate acid; carbamazepine; child; treatment outcome; drug incompatibility.

Uvod. Karbamazepin može dovesti do pogoršanja epileptičnih napada kod generalizovanih epilepsija (primarnih ili sekundarnih), koje u kliničkoj slici imaju apsanske (tipične i/ili atipične) i/mioklonusne napade. I neke okcipitalne epilepsije, međutim, mogu se pogoršati uvođenjem karbamazepina. Prikaz bolesnika. Prikazali smo dečaka, starog 10 godina, rođenog posle komplikovanog i produženog porođaja koji je završen vakuum ekstrakcijom, uređenog ranog psihomotornog razvoja. U 8 godini imao je prvi epileptični napad, tipa jednostavnog okcipitalnog, sa jednostavnim promenama kognicije i umjetnošću. Nalaz snimanja magnetnom rezonancijom (MRI) mozga ukazao je na focalne kortikalne reduktivne promene parietoocipitalno, levo. Interiktusni EEG je beležio uspoređeni osnovni dečak koji je na terapiju uveden karbamazepin, došlo je do pogoršanja napada, EEG nalaza, promene ponašanja i lošeg uspeha u školi. Isključenjem karbamazepina stanje se popravilo, kako klinički, tako i u EEG nalazu. Zaključak. Lezone okcipitalne epilepsije u detinjstvu pokazuju pogoršanje sa karbamazepinom, jer posle njegovog uvođenja dolazi do pogoršanja napada, promena ponašanja, kognicije sa pojavom dugotrajnih bilateralnih pražnjenja i posteriornih oštar talas-spori talas kompleksa visoke amplitude u EEG.

Ključne reči: epilepsije, parcijalne; konvulzije; valproinska kiselina; karbamazepin; decu; lečenje; ishod; lek, inkompatibilnost.

Introduction

The basic goal of antiepileptic therapy (AET) is to fully control seizures with a satisfactory quality of life of the patient. AET is primarily aimed at the suppression of clinical manifestation of seizures, while the expected normalization of epileptiform EEG abnormalities is a reasonable therapeutic goal. The basic precondition of successful treatment is making the correct diagnosis of epilepsy. The type of seizures, the type of epileptic syndrome and etiology of epilepsy should be de-
terminated as soon as possible, as this will influence the choice of medication, mode of treatment and prognosis. Today AET is still the first-line method in the treatment of most epilepsies, while the choice of drugs is in constant increase.

Carbamazepine (CBZ) is an antiepileptic with a wide clinical application in treatment of focal and secondary generalised tonic-clonic (GTC) seizures. Idiopathic generalized epilepsies (IGE), such as juvenile absence epilepsy, juvenile myoclonic epilepsy and epilepsy with GTC seizures on awakening feature seizure aggravation when CBZ is introduced into therapy. Epilepsies with clinical manifestations involving absences and/or myoclonic seizures, and EEG recording with bilateral generalised 4–6 Hz spike-and-wave complex discharges, show clinical and EEG worsening by introduction of CBZ. CBZ-induced aggravation of focal idiopathic epilepsies is atypical form of childhood benign epilepsies with centrotemporal spikes (atypical BECTS), atypical cases of Panayiotopoulos syndrome, and cases of late idiopathic occipital epilepsies of childhood (Gaustat type). Focal symptomatic epilepsies presenting aggravation by CBZ are occipital epilepsies of childhood with unilateral or bilateral occipital sharp-wave and slow-wave complexes recorded by EEG. CBZ is also contraindicated in the following syndromes: Dravet, Dosse, Lennox-Gastaut, Angelman, Landau-Kleffner and epileptic syndrome with bilateral continuous spike-and-wave activity during slow-wave sleep, among others. Besides, their EEGs demonstrate bilateral discharges of spike-multiple spike and slow-wave complexes at 1–2.5 Hz, which clinically often correlates with atypical absences and myoclonic seizures. Misinterpretation of focal discharges as recorded by EEG in idiopathic generalized epilepsies and consecutive inclusion of CBZ, the medication for focal seizures, leads to the paradoxical aggravation of seizures.

Case report

We reported a 10-year-old boy, body weight (BW) 63.5 kg, body height (BH) 148 cm, born of the first term pregnancy after a complicated and prolonged delivery completed by vacuum extraction, with normal early psychomotor development, normal neurological and psychiatric status, negative heredity for epilepsy, febrile attacks, inflammatory and traumatic brain disorders. At the age of 8, one morning after breakfast, the boy developed the first epileptic seizure, which, according to the patient’s case history and the parents, initiated with optical images of bright colored circles, headache, version of the eyes and head to the left, tonic-clonic convulsions right-sided at onset and later of the whole body, loss of consciousness and urination. Seizures occurred every 1–2 months, during the day only. Standard EEG demonstrated a slow basic activity above the posterior region of the left hemisphere with occasional focal sharp-slow-wave complexes or slow-waves at 4–5 Hz in the left parietal-occipital and temporal-occipital regions (Figure 1). Short bicoxipital sharp and slow-wave complexes at 1.5 Hz, amplitude exceeding 100 μV with left-sided predomination were also recorded. In view of such EEG findings in correlation with cortical MRI reductions in the left parietal-occipital region it was implicitly concluded that this was indicative of a symptomatic epileptic lesion of the occipital lobe with secondary generalization. Valproat (VAL) in the dose of 30 mg/kg/day was included into therapy, which resulted in a complete control of secondary GTC seizures over a 6-month period. As the patient still complained of occasional visual problems followed by headaches, CBZ in dose of 10 mg/kg/day was also included into therapy. After including of CBZ, GTC seizures relapsed, which led the neurologist to increase the dose of CBZ to 30 mg/kg/day, without previously performing a check-up EEG. Beside the aggravation of seizures, the parents noticed changes in the child’s behavior: he seemed withdrawn, often aggressive and performed poorly at school. Being dissatisfied with the developed situation, the parents turned to another neurologist. EEG was performed showing the presence of long-term bilateral discharges of a posterior sharp wave-slow-wave complex at 1–1.5 Hz, amplitude exceeding 300 μV (Figure 2), which are seen in aggravation by carbamazepine. On check-up, blood antiepileptic (VAL and CBZ) levels were within the therapeutic levels. Based on the deterioration of clinical features and EEG findings, it was concluded that CBZ was probably the cause of the developed condition. By withdrawal of CBZ, secondary GTC seizures ceased, as well as the long-standing
bilateral discharges of the high-voltage posterior sharp wave-slow-wave complex (Figure 3). Carbamazepine was replaced with lamotrigine, but having caused skin rash it had to be withdrawn. By a daily dose of 500 + 0 + 500 mg valproate and 25 + 0 + 25 mg topiramate, we achieved a full control even of simple occipital seizures. The patient has been without seizures for a year now, cognitive and affective disorders withdrew and his performance at school also improved.

**Discussion**

Occipital lobe epilepsies are not frequently seen in the clinical practice, and have a prevalence ranging from 5–10% of all epilepsies. They can be symptomatic, i.e. of cryptogenic etiology occurring at any age or idiopathic which as a rule occur in childhood. In symptomatic occipital lobe epilepsies about 50% of children have MRI ischemic lesions of type porencephalia, periventricular leukomalacia or cerebral infarction. The clinical semiology of seizures involves visual and oculomotor symptoms. Seizures are of simple focal type, while the occurrence of complex focal seizures is the sign of extra-occipital propagation of discharges in the parietal, temporal or frontal lobes. The visual semiology is predominated by elementary, quite rare and complex visual hallucinations, illusions and palinopsia. They are often in the form of small colorful circles moving across the visual field or rarely flashing and flickering lights. Elementary visual hallucinations are often followed by oculomotor symptoms with tonic deviation of the eyes and head, epileptic nystagmus or eye blinking. Visual hallucinations are the key symptoms suggesting an occipital focus. If visual symptoms are not marked, the semiology of seizures and standard EEG can be a frequent cause of incorrect diagnosis, as they often reflect the condition of discharges propagation and less their initiation.

Interictal EEG shows occipital spikes and/or sharp wave slow-wave complexes in 57% of cases, unilaterally or bilaterally. Biocipital discharges of sharp wave and slow wave complexes (spike and slow-wave complex) occur in epilepsies of symptomatic and idiopathic etiology. Prognosis is favorable in idiopathic and unfavorable in symptomatic epilepsy when it essentially depends on the type and size of the causal lesion. Pharmacoresistance is seen in most cases with disorders of cortical development or tumor of the occipital lobe when surgical treatment is the method of choice.

By the example of our patient the deterioration of seizures occurred when, beside VAL, CBZ was introduced into therapy in order to control simple occipital seizures followed by headaches. Despite the parents’ suggestion that seizures worsened after the introduction of CBZ, the neurologist increased CBZ dose without performing a check-up EEG; i.e. therapeutic effects of CBZ were not under concurrent clinical and EEG follow-up. CBZ can induce unusual electroclinical manifestations that can be explained by synchronization and increased bilateral EEG discharges. It is well known that CBZ can increase present or activate new bilateral EEG discharges of spike-polyspike and spike-wave complex and sharp wave-slow wave complex, and that it is contraindicated in such cases. Oxcarbazepine, vigabatrin, tiagabine and gabapentin are also contraindicated. Increased bilateral EEG discharges often result in exacerbation of seizures, as well as the occurrence of other type of seizures. It should be pointed out that it is impossible to predict the effect of an antiepileptic on the EEG of a person with epilepsy and that some patients respond to antiepileptics on individual for a group unpredictable way.

In our patient, the deterioration of EEG findings induced by CBZ correlated with the aggravation of seizures, change of behavior and cognition. Studies have shown that long-term bilateral interictal discharges of spike-wave complex or sharp wave-slow wave complex, particularly in childhood, can be followed by transitory cognitive and behavioral disorders. In children and adults with epilepsy, bilateral interictal EEG discharges of spike-polyspike and spike-wave complex or sharp wave-slow wave complex are a stable predictor of aggravation by carbamazepine. Our example shows that symptomatic lesions of occipital lobe epilepsy, which have unilateral and/or bilateral discharges of sharp-and-slow-wave complex in interictal EEG, can also manifest aggravation by CBZ. In such cases it is possible that there is also present an additional (probably genetic) factor that enables the reaction of aggravation by CBZ. Although epilepsy is primarily a clinical diagnosis, the correlation of epileptic seizures and EEG changes is necessary, both for diagnostics, as well as for the follow-up of antiepileptic therapy effects.

**Conclusion**

Epilepsy treatment with drugs inadequate for the given type of seizures has a deteriorating effect on epilepsy, and when the drug of choice causes clinical worsening correlating with the activation of new and increase of already present EEG discharges, aggravation by an antiepileptic should be taken into consideration. Lesional occipital epilepsies of childhood show aggravation by carbamazepine, which, if administered, induces aggravation of seizures, behavior changes, cognition with the occurrence of long-term bilateral discharges, and posterior sharp-wave and slow-wave high amplitude complexes recorded by EEG.
REFERENCES


Received on June 28, 2012.
Revised on October 19, 2012.
Accepted on October 23, 2012.